Document is current
Any future updates will be listed below
-
Authors
Sinnappurajar, Praisoody https://orcid.org/0000-0001-5849-3467
Ramanan, Athimalaipet V https://orcid.org/0000-0001-8663-2401
- License Information
-
More Information
Article History
Received: 24 August 2022
Revised: 24 August 2022
Accepted: 2 September 2022
First Online: 6 October 2022
Declarations
:
: AVR has received speaker and consulting fees from AbbVie, Eli Lilly, Novartis, Roche, Sobi and UCB. PS has declared no conflicts of interest.
Free to read: This content has been made available to all.
